MacroGenics
MacroGenics develops monoclonal antibody-based therapeutics for cancer treatment using proprietary next-generation antibody technology platforms and protein engineering expertise.
SCHEDULE 13G/ANov 16Latest SEC filing
Nov 12Latest story
November 2026
October 2026
September 2026
August 2026
July 2026